Background {#Sec1}
==========

Worldwide Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) is a major public health issue. In 2017, over 36.9 million people were living with HIV/AIDS. The most affected continent, Africa, had 25.7 million (70%) people with HIV/AIDS. In Ethiopia, about 710, 000 people were living with the disease as of 2017 \[[@CR1]\]. The global antiretroviral therapy (ART) coverage increased progressively from 7% in 2005 to 59% in 2017 \[[@CR2], [@CR3]\]. The estimated coverages in 2017 were 60 and 59% for Africa and Ethiopia, respectively \[[@CR1]\].

Because of this extensive ART scale-up, treatment failure has become an emerging problem \[[@CR4], [@CR5]\]. The prevalence of first-line ART failure differs significantly across countries depending on the criteria (clinical, immunological or virologic) used for its diagnosis. The viral load cut-off points to diagnose treatment failure also vary in different countries. The first-line ART virologic failure rate in Africa was 7.1 (95% CI: 5.1--9.1) per 100 patient-years of follow-up \[[@CR6]\]. In Ethiopia, studies reported virologic failure rates ranging from 5.3 to 19% \[[@CR7]--[@CR9]\], and the percentage of patients switched to second-line ART was 1.5% in 2013 \[[@CR10]\]. Switching to second-line ART means that patients are receiving more toxic medications. As a result, patients become less adherent, and AIDS progression will be more rapid, both of which make patient monitoring expensive \[[@CR11]--[@CR14]\].

Previous studies identified that suboptimal adherence, adverse drug reactions \[[@CR15], [@CR16]\], higher pre-treatment (baseline) HIV viral load level, baseline World Health Organization (WHO) AIDS stage 3 or 4, CD4 lymphocyte count \< 50 cells/mm^3^, low body mass index (BMI), drug interactions and dyspepsia as an important risk factors for treatment failure \[[@CR17]--[@CR22]\]. A study with a clear distinction between participants with and without ART failure remains important to identify predictors of treatment failure. To our knowledge, most studies from Ethiopia used clinical and immunologic criteria to assess factors that influence treatment failure. As immunologic and clinical criteria have low sensitivity and specificity to identify true ART failure \[[@CR23]\], it could be difficult to identify risk factors based on these two criteria alone. Therefore, this study aimed to investigate risk factors for first-line antiretroviral failure using the virologic (plasma viral load) criteria.

Methods {#Sec2}
=======

Study setting {#Sec3}
-------------

This study was carried out at the ART follow-up clinic of Asella Hospital, Ethiopia. The hospital gives clinical service to a total population of about 3.5 million people. There were 3238 patients with HIV/AIDS (including those from the surrounding rural areas and nearby towns) who had an ART follow-up in the hospital of which 102 (3.2%) patients were on second-line ART.

Study design and participants {#Sec4}
-----------------------------

A 1:2 matched case-control study (by age, sex and treatment duration since initiated on ART) was conducted between June 2015 to July 2017 (study period). All adult HIV-positive patients (aged ≥15 years) who were on ART for at least 6 months and whose baseline CD4 lymphocyte count and WHO HIV stage details available using the ART electronic health record of Asella Hospital were our target population. This data ranges from January 2005 to May 2017, and only patients not died and had an active follow-up at the time of the study were included. Ninety-one patients who were receiving second-line ART were selected as cases. Treatment failure status for cases was confirmed by two viral load tests (viral load ≥1000 copies/mL), performed 3 months apart as per national guideline, before a change of ART regimen. Controls were 182 patients with undetectable viral load (less than 50 copies/mL) who were taking first-line ART for at least 6 months. Details of the selection process are described below (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1The selection process of study participants. (ART = Antiretroviral therapy, VL = viral load)

For each case, two controls were selected using a lottery method after being matched by age, sex, and duration on ART. We used the following technique for selecting controls for each case. For example, for a case who commenced ART in June 2005, we used an electronic ART database to find two controls who were also initiated on ART in June 2005 with similar gender and within ±5 years of age of the case.

Variables and measures {#Sec5}
----------------------

Sociodemographic and clinical characteristics of participants were assessed for their possible association with the outcome variable (ART failure) (Table [1](#Tab1){ref-type="table"}). The variables measured before ART initiation were baseline CD4 lymphocyte count and WHO HIV stage, whereas all the other variables were retrospectively measured during patient follow-up after ART was started.Table 1Socio-demographic and baseline clinical characteristic of adult HIV-positive patients, Southeast Ethiopia, 2015--2017VariablesTotal (*N* = 273)Patients with ART failure (Cases) (*N* = 91)Patients without ART failure (Controls) (*N* = 182)Gender-male149 (55%)52 (19%)97 (36%)Median age in years (IQR)40 (11)39 (10)40 (12)Religion Orthodox Christian187 (69%)62 (23%)125 (46%) Muslim160 (21%)20 (7%)37 (14%) Protestant27 (10%)9 (3%)18 (7%) Others2 (1%)0 (0%)2 (1%)Marital status Married160 (59%)47 (17%)113 (41%) Not married113 (41%)44 (16%)69 (25%)Family size  ≤ 5 family members217 (80%)76 (28%)141 (52%)  \> 5 family members54 (20%)13 (5%)41 (15%)Educational status Illiterate39 (14%)12 (4%)27 (10%) Literate234 (86%)79 (29%)155 (57%)Employment Employed267 (98%)87 (32%)180 (66%) Unemployed6 (2%)4 (1%)2 (1%)Residence area Rural67 (25%)28 (10%)39 (14%) Urban206 (76%)63 (23%)143 (52%)Khat\*\* chewing Yes10 (4%)4 (4%)6 (3%) No263 (96%)87 (96%)176 (97%)Alcohol use Yes7 (3%)1 (1%)6 (3%) No266 (97%)90 (99%)176 (97%)Smoke cigarettes Yes6 (2%)3 (3%)3 (2%) No267 (98%)88 (97%)179 (98%)Main diet Wheat or barley40 (15%)18 (20%)22 (12%) Teff165 (60%)54 (60%)111 (61%) Others68 (25%)19 (20%)49 (27%)Poor drug absorption Main diet wheat or barley with diarrhea3 (1%)3 (3%)0 (0%) Main diet wheat or barley without diarrhea37 (14%)15 (16%)22 (12%)Duration on ART median in months (IQR)69 (41)64 (39)72 (36)Baseline CD4 lymphocyte count  \< 50 cells/mm^3^33 (12%)20 (22%)13 (7%)  ≥ 50 cells/mm^3^240 (88%)71 (78%)169 (93%)Baseline WHO HIV stage Stage 126 (10%)8 (9%)18 (10%) Stage 293 (34%)22 (24%)71 (39%) Stage 3140 (51%)52 (57%)88 (48%) Stage 414 (5%)9 (10%)5 (3%)ART regimen AZT based130 (48%)57 (63%)96 (53%) TDF based143 (52%)34 (37%)86 (47%)TB treatment while taking ART Never231 (85%)58 (64%)173 (95%) Once33 (12%)26 (28%)7 (4%) Two times8 (3%)6 (7%)2 (1%) Three or more1 (0%)1 (1%)0 (0%) Never discontinued ART212 (78%)49 (54%)163 (90%)Discontinued ART (by duration)61 (22%)42 (46%)19 (10%)  \<  1 month32 (12%)23 (25%)9 (5%)  \>  1 month29 (10%)19 (21%)10 (5%)Missed ART follow-up Never233 (85%)70 (77%)163 (89.5%) Sometimes32 (12%)14 (15%)18 (10%) Often8 (3%)7 (8%)1 (0.5%)Repeated or persistent diarrhea Yes24 (9%)16 (18%)8 (4%) No249 (91%)75 (82%)174 (96%)Psychiatric illness Yes10 (4%)6 (7%)4 (2%) No263 (96%)85 (93%)178 (98%)Dyspepsia Yes82 (30%)31 (34%)51 (28%) No191 (70%)60 (66%)131 (72%)Diabetic Yes1 (0.4%)1 (1%)0 (0%) No272 (99.6%)90 (99%)182 (100%)Hypertensive Yes3 (1%)0 (0%)3 (2%) No270 (99%)91 (100%)179 (98%)Stool *H. pylori* antigen positive Yes64 (23%)18 (20%)46 (25%) No209 (77%)73 (80%)136 (75%)HBsAg positive Yes12 (4%)3 (3%)9 (5%) No261 (96%)88 (97%)173 (95%)Anti-HCV positive Yes5 (2%)1 (1%)4 (2%) No268 (98%)90 (99%)174 (96%)VRDL positive Yes56 (20%)13 (14%)43 (24%) No217 (80%)78 (86%)139 (76%)Note: *ART*: Antiretroviral Therapy; *AZT*: Azidothymidine (Zidovudine); *HCV*: Hepatitis C virus; H. pylori: Helicobacter pylori; *HBsAg*: Hepatitis B surface antigen; *IQR*: interquartile range; *TDF*: Tenofovir; *TB*: tuberculosis; *VDRL*: Venereal disease research laboratory; *WHO*: World Health Organization. \*Teff (*Eragrostis tef*) is a gluten-free cereal traditionally grown in Ethiopia \[[@CR25]\]. \*\*Khat *(Catha edulis)* is a plant native to the Horn of Africa and the Arabian Peninsula which contains psychoactive substances that have a high abuse potential \[[@CR26]\]

Duration on ART was defined as the total time (in months) a patient was on ART since initial enrolment into ART care excluding the period of interruptions. Discontinuation of ART for a patient currently on ART was defined as having a history of complete stoppage of ART medications for any duration; whereas missed ART follow-up meant that a patient missed a drug refill date. The ART regimen for cases was their first-line ART regimen, not their current second-line regimen.

Repeated or persistent diarrhea was defined as ≥2 episodes of diarrhea or a single episode lasting more than 2 weeks, respectively. We used the term psychiatric illness in patients who were diagnosed with a disorder listed in the Diagnostic and Statistical Manual of Mental Disorders IV \[[@CR24]\]. Tuberculosis (TB) co-infection was defined as an active TB disease requiring a curative therapy with anti-TB medications. Alcohol use was defined as the use of alcoholic beverages in any amount. A main-diet constitutes the usual sum of food consumed by participants in a stable manner for years. Poor drug absorption was assumed to be present in those patients who experienced diarrhea (repeated or persistent) and frequently eat wheat or barely. For variables measuring co-existing chronic infections, we presumed that these diseases were either acquired during a similar high-risk behavior that led to the acquisition of HIV itself (hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis) or acquired early in life (HBV and Helicobacter pylori (*H. pylori*) infection).

Data collection tool and procedure {#Sec6}
----------------------------------

The data collection tools were interview-questionnaire, electronic ART database, patient chart review and virologic test for selection of controls. In addition, other laboratory tests were also performed to detect chronic carrier state for infections, including HBV, HCV, *H. pylori* and Venereal disease research laboratory (VDRL) tests for both cases and controls.

The questionnaire was first developed in English and translated into local languages, Oromiffa and Amharic, and cross-checked for consistency. It was piloted, modified and validated. Training was provided for the study team before the start of the project. The research team included the three investigators, two registered nurses who assisted patients to complete the questionnaire, five laboratory technicians and an IT professional to record all the observations into Epi-info software daily. The investigators continuously monitored the data collection process throughout the study. Data completeness was regularly checked, and any missing data were obtained on the subsequent follow-up of patients.

Data processing and analysis {#Sec7}
----------------------------

Data from Epi-Info was exported to SPSS statistics version 23.0. Descriptive statistics were used to present socio-demographic and clinical characteristics. Bivariate logistic regression analysis was carried out, and independent variables with *p*-values of ≤0.2 were included in multivariate logistic regression analysis. Prior to the multivariate analysis, multicollinearity diagnostics was performed, and there were no significant interactions between independent variables. Adjusted odds ratios (AOR) with 95% confidence intervals (CIs) were used as an effect measure. A *p*-value of equal or less than 0.05 was considered as significant. The matching factors (age, sex and duration of ART) were included in the adjusted analysis.

Ethics approval {#Sec8}
---------------

Ethical approval was obtained from the Arsi University College of Health Sciences Ethics Review Board. Informed consent was obtained from study participants. Information gathered from respondents was treated confidentially, and the norm of the community was considered and respected in the process of data collection. Patients with abnormal findings were referred to the treating physician and were provided with the appropriate care.

Results {#Sec9}
=======

Socio-demographic characteristics of participants {#Sec10}
-------------------------------------------------

Of all 273 study participants, 55% were males. The median age of the participants was 40 years. The median duration of treatment was 69 months. Most of the participants were Orthodox Christian 187 (69%), married 160 (59%), and literate 234 (86%). Approximately three-quarters of patients were living in the urban area, and 267 (98%) were employed (Table [1](#Tab1){ref-type="table"}).

When we compare the characteristics of cases with controls in terms of age, sex and duration of ART; they were roughly comparable in a 1:2 ratio. Compared with controls, cases were six times more affected with active tuberculosis and four times more likely to have persistent diarrhea (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 2Risk factors for ART failure in adult HIV-positive patients, Southeast Ethiopia, 2015--2017VariablesBivariate analysisMultivariate analysisCOR95% CIP-valueAOR95% CIP-valueIlliterate0.90.4--1.80.714Small family ≤51.50.8--2.80.245Residence in rural area1.60.9--2.90.0921.40.6--2.90.396Unemployed4.10.7--230.1051.50.1--27.20.775Unmarried1.50.9--2.60.1001.40.7--2.70.379Alcohol3.10.4--25.90.303smoking cigarette2.00.4--10.30.390Khat\*\* chewing1.30.4--4.90.650Main diet wheat or barley vs other food1.80.9--3.50.0932.30.9--5.40.064Main diet teff vs wheat or barley0.60.3--1.20.147Baseline CD4 lymphocyte count ≤50 cells/mm^3^3.71.7--7.8\< 0.0013.81.5--9.60.005Baseline WHO stage 43.91.3--12.00.0180.30.1--1.40.138Discontinuation of ART7.43.9--13.8\< 0.0019.84.0--23.8\< 0.001\<  1 month8.53.7--19.6\< 0.001\>  1 month6.32.8--14.5\< 0.001AZT based regimen1.50.9--2.50.1211.30.7--2.60.392Missed ART follow-up2.61.3--5.10.0071.60.6--4.80.362Repeated or persistent diarrhea4.61.9--11.3\< 0.0014.41.5--13.20.007Dyspepsia1.30.8--2.30.305Psychiatric illness3.10.9--11.40.0820.60.3--1.50.272Anti-HCV positive2.00.2--18.40.531HBsAg positive1.50.04--5.80.534H. pylori antigen positive0.70.4--1.30.314VDRL positive0.50.3_1.10.0740.60.3--1.50.272Note: *ART*: Antiretroviral Therapy; *AZT*: Azidothymidine (Zidovudine); *CI*: Confidence interval; *COR*: Crude odds ratio; *HCV*: Hepatitis C virus; *H*. pylori: Helicobacter pylori; *HBsAg*: Hepatitis B surface antigen; *VDRL*: Venereal disease research laboratory; *WHO*: World Health Organization. \*Teff (*Eragrostis tef*) is a gluten-free cereal traditionally grown in Ethiopia \[[@CR25]\]. \*\* Khat *(Catha edulis)* is a plant native to the Horn of Africa and the Arabian Peninsula and contains psychoactive substances that have a high abuse potential \[[@CR26]\]

Discussion {#Sec11}
==========

This study identified discontinuation of ART, baseline CD4 lymphocyte count ≤50 cells/mm^3^ and persistent diarrhea as independent factors for first-line ART failure. The risk of ART failure was high and comparable whether the duration of ART discontinuation was greater or less than 1 month. Frequent eating of a diet made of wheat or barely showed a trend of statistically significant association with first-line ART failure.

Patients who did experience first-line ART failure were nearly 10 times more likely to have a history of total ART discontinuation (AOR = 9.8, 95% CI: 4.0--23.8) than those who did not. The risk of ART failure in patients who discontinued ART for more than 1 month (COR = 6.3, 95% CI: 2.8--14.5) was comparable with those who discontinued it for less than 1 month (COR = 8.5, 95% CI: 3.7--19.6). The association between ART failure and drug discontinuation was also significant in other studies conducted in a similar setting. Comparable findings were reported by case-control studies from Zimbabwe (AOR = 5.1, 95% CI 2.8--10.0) \[[@CR19]\], Tanzania (AOR = 12.0, 95% CI 2.1--69.3) \[[@CR27]\] and the northern part of Ethiopia (AOR = 15.80, 95% CI: 6.9--36.5) \[[@CR28]\].

Patients who were initiated on ART at an advanced stage of HIV/AIDS (baseline CD4 lymphocyte count ≤50 cells/mm^3)^ were four times more likely to experience first-line ART failure (AOR = 3.8, 95% CI: 1.5--9.6) in this study. Several studies reported that starting ART late in patients with advanced immunosuppression is associated with antiretroviral treatment failure \[[@CR17], [@CR29]--[@CR33]\].

Persistent diarrhea was also found to be an independent predictor of ART failure (AOR = 4.4, 95% CI: 1.5--13.2) as documented in other studies \[[@CR34], [@CR35]\]. Poor absorption of ART medications associated with a general malabsorption state could occur in patients with persistent diarrhea. However, this finding could be an overestimation as persistent diarrhea could be a manifestation of ART failure itself with disproportionately more diarrheal cases among the cases group.

Furthermore, frequent eating of wheat or barley-based meal (AOR = 2.3, 95% CI: 0.9--5.4) showed a trend to be a risk factor for first-line ART failure (*p*-value \< 0.064) compared with other food. It is important to note that wheat and barley are gluten-containing foods, and both foods accelerate gastrointestinal transit \[[@CR36], [@CR37]\]. Compared to barley and wheat, frequent eating of teff, which is a gluten-free staple grain of Ethiopian cuisine \[[@CR25]\], showed a decreased odds ratio for ART failure (COR = 0.6, 95% CI: 0.3--1.2). To our knowledge, there are no previous studies that documented frequent eating of wheat and barley-based diet as a risk factor for first-line ART failure, and further studies with larger sample size are required before generalizing.

Our study has several limitations. Most of the independent variables were self-reported. Therefore, memory bias and imperfect temporal precedence could have under or overestimated our results. The smaller study population and sensitivity and specificity of laboratory tests might also have affected the accuracy of our findings.

Conclusions {#Sec12}
===========

Discontinuation of ART drugs, persistent diarrhea and baseline CD4 lymphocyte count ≤50 cells/mm^3^ were strongly associated with first-line ART failure. Our findings underscore the importance of avoiding ART discontinuation of any duration to prevent treatment failure. Wheat or barley as the main diet could be a possible cause for ART failure; however, further studies are needed.
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